LSTALisata Therapeutics, Inc.

LSTA Stock Price, Valuation & Chart | Lisata Therapeutics, Inc.

Compare

$1.570+0.00 (+0.00%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology LSTA intrinsic value LSTA calculated fair value vs price

Overview Financials Dividends Ratios

LSTA Historical price chart

LSTA Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization14.30M

PE Ratio-0.96

EPS-1.64

Trading Volume113.61K

Today's High/Low1.6/1.45

Dividend Yield0.00

52 Week High/Low5.07/0.99

Shares Outstanding9.11M

LSTA Financial Statement

LSTA Analyst ratings

LSTA Analysis & performance metrics

LSTA Company profile

Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the…

Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb…

LSTA Management team

Name

Position

Kristen K. Buck M.D.

Executive Vice President of R&D and Chief Medical Officer

John D. Menditto

Vice President of Investor Relations & Corporate Communications

James Nisco

Senior Vice President of Finance, Treasurer, CAO & Principal Financial and Accounting Officer

Gregory S. BerkinCTO

Chief Information & Data Protection Officer

David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D.CEO

President, Chief Executive Officer & Director

Tariq Imam

Senior Vice President of Business Development & Operations and General Counsel

William K. Sietsema Ph.D.

Vice President of Global Regulatory Affairs

Name

Position

Kristen K. Buck M.D.

Executive Vice President of R&D and Chief Medical Officer

John D. Menditto

Vice President of Investor Relations & Corporate Communications

James Nisco

Senior Vice President of Finance, Treasurer, CAO & Principal Financial and Accounting Officer

Gregory S. BerkinCTO

Chief Information & Data Protection Officer

David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D.CEO

President, Chief Executive Officer & Director

Tariq Imam

Senior Vice President of Business Development & Operations and General Counsel

William K. Sietsema Ph.D.

Vice President of Global Regulatory Affairs

Management Team

Kristen K. Buck M.D.

Executive Vice President of R&D and Chief Medical Officer

John D. Menditto

Vice President of Investor Relations & Corporate Communications

James Nisco

Senior Vice President of Finance, Treasurer, CAO & Principal Financial and Accounting Officer

Gregory S. BerkinCTO

Chief Information & Data Protection Officer

David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D.CEO

President, Chief Executive Officer & Director

Tariq Imam

Senior Vice President of Business Development & Operations and General Counsel

William K. Sietsema Ph.D.

Vice President of Global Regulatory Affairs

Management

Kristen K. Buck M.D.

Executive Vice President of R&D and Chief Medical Officer

John D. Menditto

Vice President of Investor Relations & Corporate Communications

James Nisco

Senior Vice President of Finance, Treasurer, CAO & Principal Financial and Accounting Officer

Gregory S. BerkinCTO

Chief Information & Data Protection Officer

David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D.CEO

President, Chief Executive Officer & Director

Tariq Imam

Senior Vice President of Business Development & Operations and General Counsel

William K. Sietsema Ph.D.

Vice President of Global Regulatory Affairs

Total 7 executives

LSTA Frequently asked questions

What is Lisata Therapeutics, Inc. (LSTA) Stock Price?

Current stock price of Lisata Therapeutics, Inc. (LSTA) stock is $1.570. The stock price is +0.00% higher in the session. The intraday range can be seen from this page. Volume of Lisata Therapeutics, Inc. (LSTA) stock is 113.61K.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Lisata Therapeutics, Inc. (LSTA) stock price going up or down today?

The stock price of Lisata Therapeutics, Inc. (LSTA) can change with earnings, company news, and overall market sentiment. Lisata Therapeutics, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Lisata Therapeutics, Inc. stock expensive at its current price?

Whether Lisata Therapeutics, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for LSTA on this page is -0.96. EPS on this page is -1.64. Compare those figures with peers and growth expectations before deciding if the current Lisata Therapeutics, Inc. price is justified.

How has the stock price of Lisata Therapeutics, Inc. (LSTA) performed historically?

Historical performance for Lisata Therapeutics, Inc. (LSTA) is shown on the price chart on this page. Review multi-period moves alongside volume to see how LSTA reacted to past earnings and market events.

Should I buy Lisata Therapeutics, Inc. (LSTA) stock, at this price?

Buying Lisata Therapeutics, Inc. (LSTA) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.